Ethnic differences in the distribution of CYP3A5 gene polymorphisms

被引:35
作者
Quaranta, S.
Chevalier, D.
Allorge, D.
Lo-Guidice, J. M.
Migot-Nabias, F.
Kenani, A.
Imbenotte, M.
Broly, F.
Lacarelle, B.
Lhermitte, M.
机构
[1] Fac Pharm Marseille, FRE 2737, CNRS, F-13385 Marseille, France
[2] Fac Med & Pharm Lille, Lille, France
[3] IRD, Cotonou, Benin
[4] Fac Med Monastir, Biochim Lab, Unite Rech 5 UR 0909, Monastir, Tunisia
关键词
CYP3A5; polymorphisms; ethnic differences; allele frequency;
D O I
10.1080/00498250600944300
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The genetic polymorphism affecting the CYP3A5 enzyme is responsible for interindividual and interethnic variability in the metabolism of CYP3A5 substrates. The full extent of the CYP3A5 genetic polymorphism was analysed in French Caucasian, Gabonese and Tunisian populations using a polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) strategy. In the three populations, eight, 17 and ten single nucleotide polymorphisms (SNPs), respectively, were identified, among which nine correspond to rare new mutations. Also identified were 16 alleles including eight new allelic variants. Significant differences were observed in the distribution of these alleles. Particularly, the frequency of the GYP3A5*3C null allele in French Caucasians (81.3%) and in Tunisians (80.0%) is higher than in the Gabonese population (12.5%) (p < 0.001). Considering the CYP3A5 genotypes of the tested individuals, only 10.4% of French Caucasians and 30.0% of Tunisians were identified as CYP3A5 expressors. In contrast, 90.0% of Gabonese subjects appear to express the CYP3A5 protein.
引用
收藏
页码:1191 / 1200
页数:10
相关论文
共 28 条
[1]
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation [J].
Anglicheau, D ;
Thervet, E ;
Etienne, I ;
De Ligny, BH ;
Le Meur, Y ;
Touchard, G ;
Büchler, M ;
Laurent-Puig, P ;
Tregouet, D ;
Beaune, P ;
Daly, A ;
Legendre, C ;
Marquet, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :422-433
[2]
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[3]
CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations [J].
Cauffiez, C ;
Pottier, N ;
Tournel, G ;
Lo-Guidice, JM ;
Allorge, D ;
Chevalier, D ;
Migot-Nabias, F ;
Kenani, A ;
Broly, F .
XENOBIOTICA, 2005, 35 (07) :661-669
[4]
Sequence analysis, frequency and ethnic distribution of VNTR polymorphism in the 5′-untranslated region of the human prostacyclin synthase gene (CYP8A1) [J].
Chevalier, D ;
Allorge, D ;
Lo-Guidice, JM ;
Cauffiez, C ;
Lepetit, C ;
Migot-Nabias, F ;
Kenani, A ;
Lhermitte, M ;
Broly, F .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2002, 70 (1-2) :31-37
[5]
THE ROLE OF INDIVIDUAL HUMAN CYTOCHROMES-P450 IN DRUG-METABOLISM AND CLINICAL-RESPONSE [J].
CHOLERTON, S ;
DALY, AK ;
IDLE, JR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (12) :434-439
[6]
Chou FC, 2001, DRUG METAB DISPOS, V29, P1205
[7]
An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: Experience in Singapore [J].
Chowbay, B ;
Zhou, SF ;
Lee, EJD .
DRUG METABOLISM REVIEWS, 2005, 37 (02) :327-378
[8]
Significance of the minor cytochrome P450 3A isoforms [J].
Daly, AK .
CLINICAL PHARMACOKINETICS, 2006, 45 (01) :13-31
[9]
Pharmacogenomics and individualized drug therapy [J].
Eichelbaum, M ;
Ingelman-Sundberg, M ;
Evans, WE .
ANNUAL REVIEW OF MEDICINE, 2006, 57 :119-137
[10]
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [J].
Fellay, J ;
Marzolini, C ;
Meaden, ER ;
Back, DJ ;
Buclin, T ;
Chave, JP ;
Decosterd, LA ;
Furrer, H ;
Opravil, M ;
Pantaleo, G ;
Retelska, D ;
Ruiz, L ;
Schinkel, AH ;
Vernazza, P ;
Eap, CB ;
Telenti, A .
LANCET, 2002, 359 (9300) :30-36